Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.

PloS one - 1 Jan 2013

Tahiri Andliena, Røe Kathrine, Ree Anne H, de Wijn Rik, Risberg Karianne, Busch Christian, Lønning Per E, Kristensen Vessela, Geisler Jürgen

Abstract excerpt

BACKGROUND: Treatment of metastatic malignant melanoma patients harboring BRAF(V600E) has improved drastically after the discovery of the BRAF inhibitor, vemurafenib. However, drug resistance is a recurring problem, and prognoses are still very bad for patients harboring BRAF wild-type. Better markers for targeted therapy are therefore urgently needed. METHODOLOGY: In this study, we assessed the individual kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Mutant Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Sulfonamides

Share to Sunitinib

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24023633
DOI: 10.1371/journal.pone.0072692
PMCID: PMC3758344

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.PMID 24023633Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Vemurafenib: the first drug approved for BRAF-mutant cancer.Semantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.Semantic proximity Read ↗

Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier functionSemantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblastsSemantic proximity Read ↗

Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.Semantic proximity Read ↗

High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.